Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Cognitive Impairment Is a Negative Prognostic Indicator in ALS: A Population Based Study
Anterior Horn
(-)
003
Authors/Disclosures
Marwa Elamin, MD (University College Hospital Galway) Dr. Elamin has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche .
No disclosure on file
Julie Phukan, MB, BCh, MRCPI No disclosure on file
Susan C. Byrne, MD No disclosure on file
No disclosure on file
Niall Pender, PhD No disclosure on file
Orla Hardiman, MD, FRCP, FAAN (Trinity Biomedical Sciences Institute) Dr. Hardiman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Wave Pharmaceuticals. Dr. Hardiman has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Cytokinetics . Dr. Hardiman has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Hardiman has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Taylor and Francis. The institution of Dr. Hardiman has received research support from Science Foundation Ireland. The institution of Dr. Hardiman has received research support from HRB.
Michael E. Shy, MD, FAAN (University of Iowa) Dr. Shy has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Applied Therapeutics. The institution of Dr. Shy has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for DTx Pharma. The institution of Dr. Shy has received research support from NIH. The institution of Dr. Shy has received research support from Muscular Dystrophy Association. The institution of Dr. Shy has received research support from Charcot Marie Tooth Association. The institution of Dr. Shy has received research support from Applied Therapeutics.